| Literature DB >> 35778434 |
Katharina Schiller1,2, Tamir Avigdor1, Chifaou Abdallah1, Viviane Sziklas1, Joelle Crane1, Ambra Stefani3, Laure Peter-Derex4, Birgit Frauscher5,6.
Abstract
Sleep spindles are the hallmark of N2 sleep and are attributed a key role in cognition. Little is known about the impact of epilepsy on sleep oscillations underlying sleep-related functions. This study assessed changes in the global spindle rate in patients with epilepsy, analysed the distribution of spindles in relation to the epileptic focus, and performed correlations with neurocognitive function. Twenty-one patients with drug-resistant focal epilepsy (12 females; mean age 32.6 ± 10.7 years [mean ± SD]) and 12 healthy controls (3 females; 24.5 ± 3.3 years) underwent combined whole-night high-density electroencephalography and polysomnography. Global spindle rates during N2 were lower in epilepsy patients compared to controls (mean = 5.78/min ± 0.72 vs. 6.49/min ± 0.71, p = 0.02, d = - 0.70). Within epilepsy patients, spindle rates were lower in the region of the epileptic focus compared to the contralateral region (median = 4.77/min [range 2.53-6.18] vs. 5.26/min [2.53-6.56], p = 0.02, rank biserial correlation RC = - 0.57). This decrease was driven by fast spindles (12-16 Hz) (1.50/min [0.62-4.08] vs. 1.65/min [0.51-4.28], p = 0.002, RC = - 0.76). The focal reduction in spindles was negatively correlated with two scales of attention (r = - 0.54, p = 0.01; r = - 0.51, p = 0.025). Patients with focal epilepsy show a reduction in global and local spindle rates dependent on the region of the epileptic focus. This may play a role in impaired cognitive functioning. Future work will show if the local reduction in spindles can be used as potential marker of the epileptic focus.Entities:
Mesh:
Year: 2022 PMID: 35778434 PMCID: PMC9249850 DOI: 10.1038/s41598-022-15147-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Patient demographics.
| ID | Age, Sex | Handed-ness | Epileptic Focus | EEG Findings | MRI findings | Medication at day of HD-EEGa | Generator | SEEG | Surgery, Outcome > 1 year | Pathology |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 26, F | R | L mesio-temporal | Interictal: T3, T9, FT9, FT7, F9 > T5, F7 (frequent) or F10, T10, T4, F8, Zy2, P10 *Ictal: L posterior temporal (T3, T5, P9) | Normal | Lamotrigine 550 mg Lacosamide 500 mg Perampanel 8 mg | Deep | X | RFTC, Ia | |
| 2 | 18, F | R | R temporo-occipital | Interictal: PO8 > P12, T6, P10, O2, PO4 *Ictal: R temporo-occipital (T6, P10, O2) | Normal | Carbamazepine 1000 mg Perampanel 8 mg | Intermediate | X | R temporo-occipital resection, n.a | FCD IIa |
| 3 | 41, F | R | R mesio-temporal | Interictal: F8, T4, F10, T10, FT8, FT10, FT12 (frequent) or F7, T3, F9, T9, FT9, FT7 *Ictal: R temporal (F8, T4, F10, T10) or bitemporal (F8, T4, F10, T10 and F7, T3, F9, T9) | R MTS | Lacosamide 200 mg | Deep | R anterior temporal lobectomy, Ia | Hippocampal sclerosis | |
| 4 | 25, F | L | L mesio-temporal | Interictal: F7, F9, T9, FT9, F11, FT11 *Ictal: L temporal (F7, T3, F9, T9, Zy1) | L MTS | Lamotrigine 100 mg | Deep | |||
| 5 | 51, F | R | R mesio-temporal | Interictal: F8, T4, F10, T10, FT10, AF8, F12 *iEEG: R temporal (F8, T4, F10, T10, Zy2) | R hippocampal atrophy | Levetiracetam 3000 mg | Deep | – | R anterior temporal lobectomy, Ia | Hippocampal sclerosis |
| 6 | 20, M | R | L dorsolateral prefrontal | Interictal: F3, C3, F5, FC5, FC3, FC1 *Ictal: L fronto-temporal (F3, C3 > F7, T3, F9, T9) | L frontocentral ischemic encephalo-malacic lesion | Lacosamide 400 mg Lamotrigine 175 mg | Superficial | – | L dorsolateral frontal resection, Ia | Gliosis, FCD IIa |
| 7 | 23, M | R | R parietal operculum/posterior insula | Interictal: C4, P4, Pz, CPz, P2, P6, CP2, CP4, CP6 *Ictal: R centro-parietal (C4, P4, Pz) | R parietal operculum/ posterior insula FCD | Carbamazepine 1600 mg Levetiracetam 1000 mg | Intermediate | – | – | |
| 8 | 24, M | R | R frontopolar | Interictal: Fp2, SO2, AF8, AF4, AFz, F4, Fz > Fp1, F3, AF7, AF3 *Ictal: R frontopolar (SO2, Fp2) | R frontopolar FCD | Carbamazepine 800 mg | Superficial | – | – | |
| 9 | 43, F | R | R parietal | Interictal: TP8, FT12, FT10, P10, T4, T6, T10 *Ictal: R hemisphere | Normal | Lacosamide 100 mg BID Levetiracetam1500 mg Carbamazepine 1100 mg | Superficial | X | – | |
| 10 | 40, F | R | L posterior temporal | Interictal: F7, T3, T5, F9, T9, Zy1 *Ictal: L posterior temporal region (T5, T3, P9) | Normal | Lacosamide 100 mg | Deep | – | – | |
| 11 | 43, M | L | R mesio-temporal | Interictal: F8, T4, F10, FT8, FT10 *Ictal: R temporal (F10, T10, F8, T4, Zy2) | R MTS | Lamotrigine 75 mg Carbamazepine 400 mg | Deep | – | – | |
| 12 | 35, M | R | L mesio-temporal | Interictal: F7, F9, FT9, F11, FT11 > Fp1, SO1 *Ictal: L temporal region (F7, T3, Zy1) | L temporal lobe atrophy affecting mesial structures | Clobazam 10 mg | Deep | – | – | |
| 13 | 43, F | R | R insula | Interictal: spike negative *Ictal: R posterior temporal region (T6, P4, P10) | Severe bilateral frontal atrophy | Oxcarbazepine 2100 mg Clobazam 30 mg | Deep | X | – | |
| 14 | 51, M | R | L mesio-temporal | Interictal: spike negative *Ictal: L temporal (F9, T9, Zy1 > F7, T3) | L mesio-temporal FCD or low-grade tumor | Lacosamide 400 mg | Deep | – | – | |
| 15 | 40, F | R | R frontal operculum | Interictal: Fp2, SO2, F10, AF8, Zy2, Fpz *Ictal: no EEG changesb | R prefrontal cavernoma | Eslicarbazepine 1200 mg Lamotrigine 350 mg Clobazam 30 mg Primidone 125 mg | Superficial | X | R fronto-operculum resection, Ia | FCD IIa |
| 16 | 21, F | R | R mesio-temporal | Interictal: spike negative *Ictal: R hemispheric | Normal | Lamotrigine 400 mg Clobazam 10 mg | Deep | X | R anterior temporal lobectomy, n.a | FCD I |
| 17 | 24, M | Ambi-dextrous | L mesio-temporal | Interictal: spike negative *Ictal: L Temporal (F7, T3, F9, T9) | L mesio-temporal cystic lesion | Levetiracetam 3000 mg Lamotrigine 375 mg Lacosamide 400 mg | Deep | – | – | |
| 18 | 19, F | R | R temporo-occipital | Interictal: T4, T6, TP8, TP10 > C4, P4 *Ictal: R temporo-occipital (O2 > T6, P10, P4) | R lingual encephalo-malacic lesion | Lacosamide 200 mg Levetiracetam 1000 mg | Deep | – | R occipital resection, n.a | Mild FCD |
| 19 | 32, M | R | R posterior temporal/ posterior insula | Interictal: T4, T6, P12, PO8, TP8 *Ictal: R posterior temporal (T4, T6, T10, P10) | R temporal neocortex atrophy & atrophy/ agenesis of the right piriform | Lacosamide 250 mg Brivaracetam 100 mg Eslicarbazepine 800 mg | Intermediate | X | – | |
| 20 | 27, F | L | R latero-occipital | Interictal: P10, T6, O2 > PO8, TP10, TP8, TP12, F8, T4 *Ictal: R posterior temporal (T6, P10) | Normal | Levetiracetam 3250 mg Lacosamide 400 mg | Superficial | X | – | |
| 21 | 40, M | R | L mesio-temporal | Interictal: FT11, FT9, T9, P9, TP9, P11, TP11, P9, TP9, T9 *Ictal: L temporal (F7, T3, F9, T9) | L fusiform lesion | Levetiracetam 2000 mg Carbamazepine 1200 mg | Deep | X | – |
F female, M male, R right, L left, MTS mesial temporal sclerosis, FCD focal cortical dysplasia, RFTC radiofrequency thermocoagulation, n.a. not applicable (follow up duration < 1 year).
*Ictal data were recorded during the stay in the monitoring unit, no seizure was registered during the night of the HD-EEG recording.
aAntiseizure medication was not significantly different between the time of the HD-EEG recording and the day of neuropsychological testing.
bThis patient does not have significant EEG changes at the time of the seizures and the focus was found to be superficial. In order to see epileptic activity at the scalp level in the EEG, an area > 8–10 cm2 of activation is required even if the generator is superficial[16]. SEEG confirmed at the moment of the clinical manifestation that the ictal activity was very focal and only involved a few electrode contacts.
Figure 1Workflow of the study procedures.
Sleep macrostructure in patients with epilepsy (n = 21) compared to healthy controls (n = 12) from the current study and compared to a larger healthy control population (n = 100) from Mitterling et al.[28].
| Sleep parameter | Patients with epilepsy (n = 21) | Healthy controls (n = 12) | Difference patients vs. controls (n = 12) | Healthy controls (n = 100) from Mitterling et al.[ | Difference patients vs. controls (n = 100) |
|---|---|---|---|---|---|
| TIB (min) | 493.0 [278.1; 721.0] | 537.7 [475.9; 590.9] | p = 0.49 | 480.0 [420.0; 504.0] | p = 0.27 |
| TST (min) | 431.5 [213.0; 660.5] | 437.5 [225.0; 563.0] | p = 0.83 | 403.0 [165.5; 458.0] | p = 0.15 |
| Sleep efficiency (% TIB) | 85.7 [66.1; 95.7] | 81.3 [46.7; 95.3] | p = 0.30 | 86.4 [36.9; 98.1] | p = 0.79 |
| Sleep onset latency (min) | 19.0 [7.0; 54.4] | 8.7 [3.0; 36.0] | 16.1 [2.9; 119.0] | p = 0.20 | |
| REM sleep latency (min) | 154.2 [65.1; 369.5] | 180.6 [65.5; 447.5] | p = 0.11 | 119.0 [49.5; 396.5] | p = 0.01 |
| N1 (% TIB) | 6.4 [2.3; 14.6] | 7.7 [2.5; 23.6] | p = 0.78 | 9.2 [3.3; 34.6] | |
| N2 (% TIB) | 40.0 [13.7; 51.1] | 38.3 [24.0; 55.0] | p = 0.99 | 42.2 [15.5; 58.9] | p = 0.07 |
| N3 (% TIB) | 22.6 [11.0; 28.2] | 19.9 [9.6; 45.7] | p = 0.24 | 15.9 [0; 36.6] | |
| REM (% TIB) | 17.7 [4.5; 28.8] | 13.0 [0.6; 18.4] | 12.5 [0.9; 24.7] | ||
| WASO (% TIB) | 7.2 [1.4; 27.1] | 12.9 [2.4; 46.0] | p = 0.32 | 11.2 [1.8; 58.7] | p = 0.15 |
TIB time in bed, TST total sleep time, WASO wake after sleep onset.
Significant values are in bold.
Figure 2Mean spindle rates per region (frontal, central, temporal, parietal, occipital and midline) in healthy controls and patients with epilepsy for all N2 epochs.
Figure 3Decrease (%) in (a) all spindle (10–16 Hz), (b) fast spindle (12–16 Hz) and (c) slow spindle (10–12 Hz) rates for the region with the epileptic focus compared to the contralateral side in early N2 sleep. Each point (circle or triangle) represents a patient.
Neuropsychological findings in patients with epilepsy (n = 21).
| ID | Visual attention—speed (automatic detection) | Visual attention—speed (controlled search) | Visual attention—accuracy (automatic detection) | Visual attention—accuracy (controlled search) | Verbal memory |
|---|---|---|---|---|---|
| 1 | 29 | 28 | 55 | 60 | 66.7 |
| 2 | 36 | 35 | 25 | 36 | 50 |
| 3 | 50 | 50 | 57 | 59 | 92.8 |
| 4 | n.a. | n.a. | n.a. | n.a. | 85.7 |
| 5 | 35 | 32 | 51 | 33 | 90 |
| 6 | n.a. | n.a. | n.a. | n.a. | 85.7 |
| 7 | 41 | 41 | 45 | 51 | 100 |
| 8 | 61 | 61 | 20 | 20 | 83.3 |
| 9 | 32 | 29 | 40 | 38 | 66.7 |
| 10 | 46 | 48 | 51 | 52 | 50 |
| 11 | 63 | 65 | 45 | 53 | 69.2 |
| 12 | 31 | 24 | 57 | 45 | 42.9 |
| 13 | n.a. | n.a. | n.a. | n.a. | 100 |
| 14 | 29 | 30 | 49 | 55 | 83.3 |
| 15 | 52 | 53 | 54 | 54 | 91.7 |
| 16 | 38 | 38 | 53 | 52 | 71.4 |
| 17 | n.a. | n.a. | n.a. | n.a. | 66.7 |
| 18 | n.a. | n.a. | n.a. | n.a. | 80 |
| 19 | 59 | 60 | 52 | 56 | 50 |
| 20 | n.a. | n.a. | n.a | n.a | 72.7 |
| 21 | 52 | 39 | 53 | 57 | 72.7 |
Performance of visual attention task is reported in T-values, verbal memory performance in % of acquired words retained at delayed recall.
n.a. not available.
Figure 4Correlation between decrease (%) in fast spindle rates (region with the epileptic focus compared to contralateral side) in N2 sleep and (a) selective attention task for speed subscale “automatic search”, (b) selective attention task for speed subscale “controlled search” and (c) verbal memory test. Grey shading represents 95% confidence interval.